NAVREF is pleased to release its 2026 Industry Partner Consortium (IPC) Annual Report, Accelerating Impact: Strategic Actions to Power Up VA’s Research Partnerships for Veterans. The report outlines concrete, actionable recommendations to strengthen VA–industry collaboration and expand access to high-impact clinical trials for veterans nationwide. 

As the VA enters its second century of research, and amid unprecedented private-sector interest in partnering with the Department, this year’s report highlights the VA’s unique strengths: a nationally integrated healthcare system, more than 9 million enrolled veterans, world-class clinician-investigators, and unparalleled real-world data infrastructure. 

Drawing on insights from NAVREF’s IPC members, the report focuses on three strategic priorities: 

• Streamlining legal and regulatory processes to accelerate clinical trial start-up and reduce uncertainty for sponsors 

• Leveraging VA site-level data to improve trial design, site selection, and veteran access 

• Optimizing EHR modernization to enhance trial matching, recruitment, and engagement 

These recommendations aim to position the VA as the nation’s leading environment for inclusive, efficient, and veteran-centered clinical research while delivering faster access to innovative therapies. 

NAVREF extends its gratitude to its IPC members—AstraZeneca, BCG, BioAffinity Technologies, Booz Allen Hamilton, Bristol Myers Squibb, Cognition Therapeutics, Eli Lilly & Company, Genentech, GSK, Johnson & Johnson, Pfizer, Siemens Healthineers, Smith+Nephew, and Takeda—whose support and collaboration have been instrumental in advancing this work. 

To view the full report, click here.